Key result
Speed modulation to introduce pulsatile flow in the HeartWare HVAD did not improve hemocompatibility compared to continuous flow over 5 hours in an in vitro blood circulation loop.
Why the study?
Does pulsatile flow improve hemocompatibility biomarkers compared to continuous flow in an in vitro HeartWare HVAD model?
Does pulsatile flow improve hemocompatibility biomarkers compared to continuous flow in an in vitro HeartWare HVAD model?
In an in vitro model, introducing pulsatile flow to the HeartWare HVAD did not improve hemocompatibility biomarkers compared to standard continuous flow over 5 hours.
No takes yet. Share an insight, caveat, or question.
Pulsatile flow via HVAD speed modulation confers no short-term hemocompatibility benefit in vitro; leaves open need for in vivo or longer-term evaluation.
Horobin et al. (2018) studied Hemocompatibility of rotary blood pumps. Pulsatile flow mode vs. Continuous flow mode (3282 rev/min) was evaluated on Hemocompatibility biomarkers (platelet aggregation, ADAMTS13, vWf, pfHb, RBC deformability, RBC-NOS activity). Speed modulation to introduce pulsatile flow in the HeartWare HVAD did not improve hemocompatibility compared to continuous flow over 5 hours in an in vitro blood circulation loop.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: